ArticleBrain and behavior2026
Prenatal (1-3)IGF-1 Treatment Is Ineffective and Behaviorally Detrimental in a Rat Model of Cortical Malformation.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMalformations of cortical development (MCD), a major cause of early-onset epilepsy, arise from disruptions in fetal corticogenesis, suggesting that prenatal intervention may be required to alter their developmental trajectory. Insulin-like growth factor-1 (IGF-1) has been proposed as a potential therapeutic agent due to its roles in neuronal survival, synaptogenesis, and plasticity. However, whether prenatal or prolonged early-life IGF-1 exposure can modify the trajectory of malformed cortical circuits remains unknown.
methodsPregnant dams were exposed to MAM to induce cortical malformation, and fetal brain development was assessed at embryonic day 19 (E19) using in utero MRI. Offspring were assigned to receive prenatal and/or prolonged early postnatal administration of the truncated IGF-1 analog (1-3)IGF-1. Outcomes after IGF-1 treatment were evaluated across multiple domains, including brain morphology, body growth, seizure susceptibility, neurometabolic profiles (
resultsFetal MRI revealed significantly reduced brain size in MAM-exposed fetuses, indicating that structural abnormalities were already established prenatally. Neither prenatal nor prolonged postnatal (1-3)IGF-1 treatment improved whole-brain growth, neurometabolite levels, or susceptibility to N-methyl-D-aspartate-induced spasms. Moreover, long-term IGF-1 exposure led to adverse behavioral outcomes, including impaired spatial working memory in the Y-maze and increased freezing during conditioning, without affecting locomotor activity or fear recall. No beneficial effects were observed across any treatment paradigm.
conclusionAlthough IGF-1 has known neurotrophic properties, early and sustained exposure to the (1-3)IGF-1 analog did not ameliorate structural-, metabolic-, or seizure-related abnormalities and produced detrimental behavioral effects in this model of cortical malformation. These findings underscore the importance of developmental timing and molecular specificity when applying IGF-1-based interventions and caution against the assumption that earlier or prolonged treatment is necessarily beneficial in malformed cortical circuits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.